MindMed Investor Presentation Deck
November 2024, 42 slides
  1. MindMed
  2. Related Decks
  3. Investor Presentation Decks
corporate presentation i | MindMed
disclaimer | MindMed
we aim to be a global leader in brain health | MindMed
experienced leadership with a proven track record shire | MindMed
research development pipeline | MindMed
next steps and anticipated milestones for pipeline | MindMed
tartrate program overview | MindMed
key highlights of program | MindMed
potential to address large unmet needs in major brain health disorders | MindMed
clinical rationale and mechanism of action | MindMed
program overview emerge name | MindMed
strategies to address key drug class methodological considerations | MindMed
multiple layers of intellectual property and protection | MindMed
tartrate | MindMed
for gad phase program overview | MindMed
phase results in gad demonstrated week durability with effect size over double the standard of care care | MindMed
phase results in gad delivered on target product profile after single dose and support phase advancement advancement | MindMed
for gad phase study designs voyage panorama | MindMed
phase gad part a schematics two pivotal studies with complementary designs designs week ass panorama | MindMed
phase gad part schematics extension phase voyage a panorama | MindMed
phase gad part a trials primary key secondary voyage panorama | MindMed
tartrate | MindMed
decades of clinical research supports unique potential | MindMed
potential demonstrated in gad patients with depression | MindMed
for phase study design design | MindMed
phase trial schematic emerge study study week gee toe a study single dose of for | MindMed
tartrate | MindMed
phase trial of utilized standard gad design and and was aligned with draft guidance for drug class class | MindMed
phase trial schematic schematic | MindMed
treatment paradigm drug effects with no psychotherapeutic intervention intervention | MindMed
participant disposition aligned with historical expectations expectations | MindMed
participant demographics and characteristics generally balanced across groups groups | MindMed
statistically and clinically significant reductions in ham a score continued at week | MindMed
continued response and remission through week with clinical responder rate and clinical remission rate | MindMed
primary key secondary analysis support dose response relationship for in gad gad | MindMed
rapid and sustained improvements in clinical global impressions severity starting on day and continuing through week | MindMed
was well tolerated with mostly transient mild to moderate adverse events consistent with drug class expectations expectations | MindMed
most common in high dose groups demonstrate favorable tolerability profile profile | MindMed
| MindMed
differentiated mechanism of action targets key pathways a | MindMed
addressing the urgent need for novel therapies | MindMed
| MindMed
See More
MindMed
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Anxiety
Clinical trial
Recent decks by MindMed
Results
November 2023
Investor Presentation
September 2023
Investor Presentation
August 2023
Investor Presentation
June 2023
See all presentations by MindMed (8 decks)
Related decks
Bionomics
Investor Presentation
April 2022
Bionomics
Results
March 2023
Bionomics
IPO
December 2021
Bionomics
Investor Presentation
June 2022
Bionomics
Investor Presentation
October 2022
uBiome
Start Up
June 2017
ATAI
Investor Presentation
October 2022
Nuvalent
Investor Presentation
January 2024
Recent decks by MindMed
See all presentations (8 decks)
Results
November 2023
Investor Presentation
September 2023
Investor Presentation
August 2023
Investor Presentation
June 2023
Bionomics
Investor Presentation
April 2022
Bionomics
Results
March 2023
Bionomics
IPO
December 2021
Bionomics
Investor Presentation
June 2022
Bionomics
Investor Presentation
October 2022
uBiome
Start Up
June 2017
ATAI
Investor Presentation
October 2022
Nuvalent
Investor Presentation
January 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io